Premium
First‐line Intravenous Cisplatin for Deeply Invasive Bladder Cancer: Update on 70 Cases
Author(s) -
PEARSON B. S.,
RAGHAVAN D.
Publication year - 1985
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1985.tb07033.x
Subject(s) - medicine , cisplatin , cystectomy , bladder cancer , pelvis , radiation therapy , cancer , surgery , urology , chemotherapy
Summary— Seventy patients with T2–T4 NX MO bladder cancer were treated with intravenous cisplatin (100mg/m 2 q 3‐weekly) followed by radiotherapy and/or cystectomy. Objective responses to cisplatin were seen in 57%. For the first group of 50 patients (treated between August 1981 and November 1983), the actuarial survival rate at 2 years was 64%, with a median survival of 20+ months: 81% of deaths occurred within 18 months of entry. Most relapses occurred in the bladder/pelvis. A randomised, controlled study is in progress to assess the true value of this approach to the treatment of invasive bladder cancer.